2016
Epoxyeicosatrienoic acids and glucose homeostasis in mice and men
Luther JM, Brown NJ. Epoxyeicosatrienoic acids and glucose homeostasis in mice and men. Prostaglandins And Other Lipid Mediators 2016, 125: 2-7. PMID: 27448715, PMCID: PMC5035218, DOI: 10.1016/j.prostaglandins.2016.07.010.Peer-Reviewed Original ResearchConceptsEpoxyeicosatrienoic acidsInsulin sensitivityRodent modelsSoluble epoxide hydrolaseGlucose homeostasisEpoxide hydrolaseActive dihydroxyeicosatrienoic acidsPancreatic islet cell functionEffects of EETsType 2 diabetesType 1 diabetesIslet cell functionP450 epoxygenasesDihydroxyeicosatrienoic acidsPeripheral tissuesIslet cellsPharmacological inhibitionArachidonic acidDiabetesCell functionGenetic polymorphismsFavorable effectTissue expressionStable analogueCompelling evidence
2012
Cardiovascular effects of antidiabetic agents: focus on blood pressure effects of incretin-based therapies
Brown NJ. Cardiovascular effects of antidiabetic agents: focus on blood pressure effects of incretin-based therapies. International Journal Of Cardiology Cardiovascular Risk And Prevention 2012, 6: 163-168. PMID: 22433315, PMCID: PMC3422131, DOI: 10.1016/j.jash.2012.02.003.Peer-Reviewed Original ResearchConceptsGlucagon-like peptide-1Cardiovascular eventsDipeptidyl peptidase IV inhibitorsAntidiabetic agentsPeptidase IV inhibitorsBlood pressureClinical trialsPeptide-1Animal modelsType 2 diabetes mellitusIncretin-based agentsBlood pressure effectsIncretin-based therapiesIV inhibitorsLarge clinical trialsFavorable effectIschemia/reperfusionTight glucose controlOverweight diabeticsCardiovascular effectsCardiovascular riskDiabetes mellitusIntensive therapyGlucose controlThiazolidinedione rosiglitazone